EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY 4.0

Empirical Antifungal Treatment of Critically Ⅲ Patients With Influenza-Associated Acute Respiratory Distress Syndrome: A Propensity Score Weighted Observational Study

Stefan Hatzl iD, Lisa Kriegl iD, Christina Geiger iD, Caroline Wilhelmer iD, Alexander C Reisinger iD, Markus Keldorfer, Julia Auinger, Gernot Schilcher iD, Florian Krammer iD, Philipp Eller iD, Robert Krause iD

Clinical Infectious Diseases · 2026

DOI: 10.1093/cid/ciaf507 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Stefan Hatzl und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Intensive Care Unit, Medical University of Graz, Graz, Austria. Hauptthemen laut MEDLINE: Antifungal Agents, Influenza, Human, Respiratory Distress Syndrome, Pulmonary Aspergillosis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Influenza-associated pulmonary aspergillosis (IAPA) is a significant fungal complication in patients with influenza-induced acute-respiratory-distress-syndrome (ARDS). The impact of empirical antifungal treatment on IAPA incidence and outcomes remains unclear.

Methods

In this observational multicenter study (9 treatment centers), we included all consecutive patients admitted to intensive care units (ICUs) with influenza-associated ARDS between 1 September 2016 and 1 March 2025. We compared patients receiving empirical antifungal treatment with those who did not, focusing on 30-day IAPA incidence (primary outcome) and survival (secondary outcome). Propensity score weighting was used to account for baseline characteristic imbalances. IAPA cases were classified based on the Fungal-Infections-in-Adult-Patients-in-ICU (FUNDICU) consensus criteria.

Results

We included 172 patients, 61 (35%) of whom received empirical antifungal therapy (94% posaconazole). IAPA was diagnosed in 24 cases, with a median onset of 2 days after ICU admission. Of these, 20 occurred in the non-treatment group and 4 in the empirical treatment group. The 30-day IAPA incidence was 7.7% in the treatment group and 20.4% in the non-treatment group (P = .002). The sub-distributional hazard ratio (sHR) for IAPA incidence in the empirical treatment group compared with the non-treatment group was 0.21 (95% CI: 0.10–0.92, P = .045). However, there was no significant difference in 30-day ICU survival.

Conclusions

In ICU patients with influenza ARDS, empirical antifungal treatment was associated with significantly reduced IAPA incidence, but this did not translate into improved survival. Randomized controlled trials are warranted to evaluate the efficacy and safety of patients’ specific empirical antifungal treatment with regard to IAPA incidence and outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsInfluenza, HumanRespiratory Distress SyndromePulmonary AspergillosisHumansMaleFemalePropensity ScoreMiddle AgedAgedIntensive Care UnitsIncidenceTreatment OutcomeAdult

Stichwörter der Autor:innen

IAPAICUinfluenza associated aspergillosismould treatmentposaconazole

Substanzen

Antifungal Agents

Autor:innen und Institutionen

  • Department of Internal Medicine, Intensive Care Unit, Medical University of Graz, Graz, Austria.
  • Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • BioTechMed Graz, Graz, Austria.
  • Division of Infectious Diseases, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
  • Department of Children and Adolescent Medicine, Pediatric Intensive Care Unit, Medical University of Graz, Graz, Austria.

ORCID-Profile: Stefan Hatzl, Lisa Kriegl, Christina Geiger, Caroline Wilhelmer, Alexander C Reisinger, Gernot Schilcher, Florian Krammer, Philipp Eller, Robert Krause

Zitieren

APA

Hatzl, S., Kriegl, L., Geiger, C., Wilhelmer, C., Reisinger, A. C., Keldorfer, M., Auinger, J., Schilcher, G., Krammer, F., Eller, P., & Krause, R. (2026). Empirical Antifungal Treatment of Critically Ⅲ Patients With Influenza-Associated Acute Respiratory Distress Syndrome: A Propensity Score Weighted Observational Study. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf507

Vancouver

Hatzl S, Kriegl L, Geiger C, Wilhelmer C, Reisinger AC, Keldorfer M, et al. Empirical Antifungal Treatment of Critically Ⅲ Patients With Influenza-Associated Acute Respiratory Distress Syndrome: A Propensity Score Weighted Observational Study. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciaf507

BibTeX
@article{Hatzl2026,
  author = {Hatzl, Stefan and Kriegl, Lisa and Geiger, Christina and Wilhelmer, Caroline and Reisinger, Alexander C and Keldorfer, Markus and Auinger, Julia and Schilcher, Gernot and Krammer, Florian and Eller, Philipp and Krause, Robert},
  title = {Empirical Antifungal Treatment of Critically Ⅲ Patients With Influenza-Associated Acute Respiratory Distress Syndrome: A Propensity Score Weighted Observational Study},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  doi = {10.1093/cid/ciaf507}
}
Kostenlos starten →